SCHEMBL4278083

SCHEMBL4278083

CCc1nc(-c2sc(C(N)=O)nc2-c2ccccc2)no1

nearest known ligand 0.47

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 6/20 0.47
ADORA1 P30542 4/20 0.45
GAA P10253 2/20 0.43
KMT2A Q03164 2/20 0.43
MEN1 O00255 1/20 0.43
NOTUM Q6P988 1/20 0.41
ALDH1A1 P00352 2/20 0.41
HTR1A P08908 1/20 0.38
HRH3 Q9Y5N1 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4293199 0.84 ADORA2A (0.64) ADORA2AADORA1GAAKMT2AMEN1
SCHEMBL1449508 0.82 MAPT (0.55) ADORA2AADORA1GAAKMT2AMEN1
SCHEMBL4290541 0.79 ADORA2A (0.47) ADORA2AADORA1GAAKMT2AMEN1
Cyclopropane SCHEMBL15484510 0.79 ADORA2A (0.63) ADORA2AADORA1ALDH1A1
SCHEMBL1449528 0.79 ADORA2A (0.63) ADORA2AADORA1ALDH1A1
SCHEMBL12127937 0.77 ALDH1A1 (0.56) GAAKMT2AMEN1ALDH1A1NPC1
SCHEMBL1449975 0.76 ADORA2A (0.76) ADORA2AADORA1KMT2AMEN1
SCHEMBL4287362 0.76 ADORA2A (0.62) ADORA2AADORA1GAAKMT2AMEN1
SCHEMBL4285796 0.75 ADORA2A (0.64) ADORA2AADORA1GAAKMT2AMEN1
SCHEMBL4293192 0.74 ADORA2A (0.65) ADORA2AADORA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1794157-B1 2-ACYLAMINOTHIAZOLE DERIVATIVES LUNDBECK & CO AS H (DK) 2014-02-26 EP claimed
US-20090137642-A1 2-Acylaminothiazole Derivatives H. LUNDBECK A/S (DK) 2009-05-28 US claimed
EP-1794157-A1 2-ACYLAMINOTHIAZOLE DERIVATIVES H.Lundbeck A/S (DK) 2007-06-13 EP claimed
WO-2006032273-A1 2-ACYLAMINOTHIAZOLE DERIVATIVES H. LUNDBECK A/S (DK) 2006-03-30 WO claimed
EP-1794157-B1 2-ACYLAMINOTHIAZOLE DERIVATIVES LUNDBECK & CO AS H (DK) 2014-02-26 EP disclosed
US-20090137642-A1 2-Acylaminothiazole Derivatives H. LUNDBECK A/S (DK) 2009-05-28 US disclosed
EP-1794157-A1 2-ACYLAMINOTHIAZOLE DERIVATIVES H.Lundbeck A/S (DK) 2007-06-13 EP disclosed
WO-2006032273-A1 2-ACYLAMINOTHIAZOLE DERIVATIVES H. LUNDBECK A/S (DK) 2006-03-30 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090137642-A1 2-Acylaminothiazole Derivatives ADORA2A, HTR2C, ADORA2B ADORA2A 1/4885ADORA1 7/4885GAA 3441/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.